IL6 and prostate carcinoma: Due to a prospective study showing that TNFα and IL-6 levels correlate with the degree of disease, and PSA progression in prostate cancer patients, TNFα and IL-6 are currently suggested as additional markers that reflect the activity level of this disease (Michalaki et al., 2004).